Role of Menopause and Early Menarche in Breast Cancer: A Meta-Analysis of Iranian Studies

2016 ◽  
Vol In press (In press) ◽  
Author(s):  
Bibi Hajar Zahmatkesh ◽  
Afsaneh Keramat ◽  
Nasrinossadat Alavi ◽  
Ahmad Khosravi ◽  
Reza Chaman
Keyword(s):  
Breast Cancer ◽  
Meta Analysis ◽  
Early Menarche ◽  
Iranian Studies

Role of Menopause and Early Menarche in Breast Cancer: A Meta-Analysis of Iranian Studies

2016 ◽  
Vol 6 (1) ◽  
Author(s):  
Bibi Hajar Zahmatkesh ◽  
Afsaneh Keramat ◽  
Nasrinossadat Alavi ◽  
Ahmad Khosravi ◽  
Reza Chaman
Keyword(s):  
Breast Cancer ◽  
Meta Analysis ◽  
Early Menarche ◽  
Iranian Studies

Prognostic role of s-phase kinase-associated protein 2 in breast cancer: A meta-analysis

2015 ◽  
Vol 52 (7) ◽  
pp. 153
Author(s):  
S Ma ◽  
D Wang ◽  
Y Shi ◽  
N Li ◽  
H Ren ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Meta Analysis ◽  
S Phase ◽  
Prognostic Role

scholarly journals Platinum-based neoadjuvant chemotherapy for triple-negative breast cancer: a systematic review and meta-analysis

2020 ◽  
Vol 48 (10) ◽  
pp. 030006052096434
Author(s):  
Zhen-Yu Li ◽  
Zhen Zhang ◽  
Xiao-Zhong Cao ◽  
Yun Feng ◽  
Sha-Sha Ren
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Meta Analysis ◽  
Complete Response ◽  
Extensive Literature ◽  
Extensive Literature Search ◽  
Positive Breast Cancer

Background Triple-negative breast cancer (TNBC) is associated with higher aggressiveness and mortality than hormone-positive breast cancer because of the lack of approved therapeutic targets. Patients with TNBC who attain a pathological complete response (pCR) after neoadjuvant chemotherapy have improved survival. Platinum-based agents show promising activity in TNBC; however, their use remains controversial. We conducted a meta-analysis to assess the role of platinum-based agents in neoadjuvant chemotherapy in patients with TNBC. Methods We performed an extensive literature search of the Pubmed, Embase, and Cochrane databases. We calculated pooled odds ratios (OR) with 95% confidence intervals (CI) for the identified studies. Results Eight randomized controlled trials with 1345 patients were included in the analysis. The addition of platinum-based agents improved pCR compared with neoadjuvant therapy based on anthracyclines, cyclophosphamide, taxanes, and fluorouracil (49.1% vs. 35.9%; OR: 1.87, 95% CI: 1.23–2.86). Hematological adverse events were similar in both groups, except for more thrombocytopenia in the platinum-based group (OR: 7.96, 95% CI: 3.18–19.93). Conclusion The addition of platinum-based agents to neoadjuvant chemotherapy improved pCR rates in patients with TNBC, with a slight increase in hematological toxicities. Platinum-based agents might thus be an accessible and economically viable option in patients with TNBC.

The prognostic role of circulating tumor cells (CTCs) detected by RT-PCR in breast cancer: a meta-analysis of published literature

2011 ◽  
Vol 130 (3) ◽  
pp. 809-816 ◽  
Author(s):  
Shu Zhao ◽  
Yupeng Liu ◽  
Qingyuan Zhang ◽  
Hongbin Li ◽  
Minghui Zhang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Meta Analysis ◽  
Rt Pcr ◽  
Prognostic Role

Circulating tumor cells in breast cancer

2017 ◽  
Vol 2 (1) ◽  
pp. 4 ◽  
Author(s):  
Akhil Jain ◽  
Moushumi Suryavanshi ◽  
Ullas Batra ◽  
Pankaj Goyal ◽  
Dinesh Doval
Keyword(s):  
Breast Cancer ◽  
Clinical Trials ◽  
Metastatic Breast Cancer ◽  
Tumor Cells ◽  
Meta Analysis ◽  
Metastatic Breast ◽  
Predictive Marker ◽  
Serum Markers ◽  
Ultimate Outcome

<span>Breast cancer is a heterogeneous disease. Liquid biopsy is a novel diagnostic tool and may provide answers to many questions related to unevenness in prognosis and ultimate outcome. Different technologies for CTC isolation, enrichment, detection, and characterization are under evaluation. Various clinical trials and meta-analysis have been conducted to define the role of CTC in early and metastatic breast cancer. CTCs are superior to other serum markers for prognostication. Their role as predictive marker remains elusive.</span>

The role of LHRH agonists in ovarian function preservation in premenopausal women undergoing chemotherapy for early stage breast cancer: A systematic review and meta-analysis.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. 1050-1050
Author(s):  
Rodrigo Ramella Munhoz ◽  
Allan Andresson Lima Pereira ◽  
Andre Deeke Sasse ◽  
Paulo Marcelo Hoff ◽  
Tiffany A. Traina ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Ovarian Function ◽  
Early Stage ◽  
Meta Analysis ◽  
Premenopausal Women ◽  
Early Stage Breast Cancer ◽  
Lhrh Agonists ◽  
Function Preservation

scholarly journals Role of nab-paclitaxel in metastatic breast cancer: a meta-analysis of randomized clinical trials

Oncotarget ◽  
2017 ◽  
Vol 8 (42) ◽  
pp. 72950-72958 ◽  
Author(s):  
Yun Liu ◽  
Guoxin Ye ◽  
Dali Yan ◽  
Lei Zhang ◽  
Fan Fan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Clinical Trials ◽  
Metastatic Breast Cancer ◽  
Randomized Clinical Trials ◽  
Meta Analysis ◽  
Metastatic Breast

Epstein–Barr virus and risk of breast cancer: a systematic review and meta-analysis

2019 ◽  
Vol 15 (24) ◽  
pp. 2873-2885 ◽  
Author(s):  
Mohammad Farahmand ◽  
Seyed Hamidreza Monavari ◽  
Zabihollah Shoja ◽  
Hadi Ghaffari ◽  
Mehdi Tavakoli ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Epstein Barr Virus ◽  
Potential Role ◽  
Meta Analysis ◽  
Case Control ◽  
Case Control Studies ◽  
Barr Virus ◽  
Ebv Infection ◽  
Epstein Barr

Despite the numerous publications regarding the role of Epstein–Barr virus (EBV) in breast cancer development, the topic has still remained controversial. The aim of the meta-analysis was to estimate the overall prevalence of EBV in the breast cancer population, and to investigate the association between EBV and breast cancer risk. The overall prevalence of EBV was calculated 26.37% (95% CI: 22–31%) from the 44 included studies. Meta-analysis of 30 case–control studies showed that the pooled association between EBV and risk of breast cancer is odds ratio 4.74 (95% CI: 2.92–7.69; Z = 6.30; p < 0.0001). Our analyses indicate a strong statistical relationship between EBV infection and risk of breast cancer, suggesting a potential role of EBV infection in the development of breast cancer.

Sign in / Sign up

Export Citation Format

Share Document